Ibrance was first approved in 2015 as a treatment for breast cancer patients who had progressed after hormone therapy, and buoyed by expanded use as a first-line therapy has grown swiftly to reach ...

Pfizer said Thursday its drug Ibrance showed efficacy in a group of breast cancer patients who do not currently have access to the medicine, potentially expanding its use. Ibrance, which generates ...

The U.S. continues to charge significantly higher prices for prescription drugs compared with similarly wealthy countries.

The increases are to list prices, which do not include rebates to pharmacy benefit managers and other discounts.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Healthcare giant Pfizer’s IBRANCE (palbociclib) as a combination therapy has improved progression-free survival from a Phase III trial in patients with metastatic breast cancer. Unveiled ...

As with Ibrance, availability for previously-treated patients was via the CDF while additional evidence of efficacy is gathered. Kisqali and Verzenios moved to routine funding last year. Keytruda ...

While under competitive pressure from Novartis and Eli Lilly, Pfizer can tally up a unique trial win for its Ibrance in a niche breast cancer population. Although CDK4/6 inhibitors such as Ibrance ...

Pfizer's PATINA trial shows IBRANCE boosts progression-free survival in HR+/HER2+ metastatic breast cancer by over 15 months. Median PFS reached 44.3 months with IBRANCE plus standard anti-HER2 ...

Real-world data showed median OS of 54.6 months for Ibrance, 59 months for Kisqali, and 64.5 months for Verzenio. Side effects varied, with higher neutropenia in the Ibrance group and consistent ...

The trial demonstrated that the addition of IBRANCE (palbociclib) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically ...